Wikipedia -WSS

Wikipedia

author：hotspot 2025-08-28 13:05:46 - browse：32741

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Appeals court upholds limits to abortion pill

WSS

CDC advisory panel says seniors 'may' get RSV vaccine

Kidney transplant patients stopped immunosuppressants in trial

Drug firms test therapies to halt Alzheimer’s before symptoms arise

How to convince healthy people to buy insurance

As pharma fights Medicare drug negotiation, hospitals, docs silent

How Long Island became the ‘eugenics capital of the world’

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Apple is now the first public company to be valued at $3 trillion

Travis Kelce and the trap of celebrity vaccine endorsements

How to save PrEP access — and even expand it

What do new weight loss drugs mean for bariatric surgery?

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare must police algorithms in Medicare Advantage, Dems say

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Walensky prepares to leave CDC — and Congress — behind

As pharma fights Medicare drug negotiation, hospitals, docs silent

focus

Live blog: Hearing on CRISPR

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Key Senate panel to consider PBM, drug pricing reform package

Key Senate panel to consider PBM, drug pricing reform package

Radiation, mainstay of cancer treatment, begins a fade

Feds fine Medicare Advantage plans for overcharging members

focus

explore

entertainment

leisure time